Controversy came up with the VA-NEPHRON-D trial that showed a strong trend to lowering the risk of renal disease progression with dual RAAS blockade vs. monotherapy ( 40 ).
← all excerpts
Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options.
1
—
—